07-758
Anti-phospho-Flt-1 (Tyr1213) Antibody
Upstate®, from rabbit
Synonym(s):
Vascular endothelial growth factor receptor 1 (VEGFR-1), Vascular permeability factor receptor, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
polyclonal
Species reactivity:
bovine, human, goat, sheep, rat, mouse
Application:
WB
Citations:
18
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
bovine, human, goat, sheep, rat, mouse
manufacturer/tradename
Upstate®
technique(s)
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pTyr1213)
Gene Information
bovine ... Flt1(503620)
human ... FLT1(2321)
mouse ... Flt1(14254)
rat ... Flt1(54251)
General description
~180 kDa (66 kDa for the fragment tested in QC)
Immunogen
KLH-conjugated, synthetic peptide containing the sequence (...VR[pY]VN...) in which [pY] corresponds to phospho-tyrosine at residue 1213 of human Flt-1. The immunizing sequence is identical in marmoset, has 14/15 identical amino acids in rat, goat, sheep, cow, and rhesus monkey and 13/15 identical amino acids in mouse.
Application
Anti-phospho-Flt-1 (Tyr1213) Antibody detects level of phospho-Flt-1 (Tyr1213) & has been published & validated for use in WB.
Research Category
Signaling
Signaling
Research Sub Category
Growth Factors & Receptors
Growth Factors & Receptors
Biochem/physiol Actions
Recognizes phospho-Flt-1 (Tyr1213).
Physical form
ImmunoAffinity Purified
Immunoaffinity purified rabbit IgG in 0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
Recombinant Flt-1 (Catalogue No. 14-562) phosphorylated by ATP
Recombinant Flt-1 (Catalogue No. 14-562) phosphorylated by ATP
Routinely evaluated by immunoblot on recombinant Flt-1 (Catalog # 14-562) phosphorylated upon incubation with ATP
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
10 - Combustible liquids
wgk
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous, V; Ouaret, D; El Ouadrani, K; Battistella, A; Megalophonos, VF; Kamsu-Kom et al.
Clinical cancer research : an official journal of the American Association for Cancer Research null
Paul Mésange et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(11), 2548-2558 (2018-03-02)
Purpose: There is extensive cross-talk between VEGF- and EGFR-pathway signaling in colorectal cancer. However, combinations of VEGF- and EGFR-targeted monoclonal antibodies (mAb) show disappointing activity, in particular for patients with mutant RAS Previous results show that tyrosine kinase inhibitors (TKI)
Marga van de Vegte-Bolmer et al.
Malaria journal, 20(1), 381-381 (2021-09-28)
The ability to culture Plasmodium falciparum continuously in vitro has enabled stable access to asexual and sexual parasites for malaria research. The portfolio of isolates has remained limited and research is still largely based on NF54 and its derived clone
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 07-758 | 04053252673634 |